Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
Liraglutide's Effect on Weight Loss in Patients After Secondary Bariatric Surgery ; a Randomized Double-blind Controlled Study.
1 other identifier
interventional
60
1 country
1
Brief Summary
Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 9, 2022
CompletedStudy Start
First participant enrolled
March 10, 2022
CompletedFirst Posted
Study publicly available on registry
March 17, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2022
CompletedMarch 17, 2022
March 1, 2022
6 months
March 9, 2022
March 9, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Percentage Total weight loss
6 months
Percentage Excess body weight loss
6 months
Secondary Outcomes (10)
Comorbidities
6 months
Weight
6 months
BMI
6 months
HbA1C
6 months
Fasting Blood Glucose (FBG)
6 months
- +5 more secondary outcomes
Study Arms (2)
Liraglutide
EXPERIMENTALdrug starts 6 weeks post-operative until 6 months SC injection dose starting 0.6 mg/day and weekly up titrated until 3.0 mg/day
Control
NO INTERVENTIONPatients with no weight loss drug intervention after bariatric surgery
Interventions
Eligibility Criteria
You may qualify if:
- Undergone primary bariatric surgery
- Need secondary bariatric surgery due to either weight regain (regained weight to have BMI \> 35) or medical associated diseases
You may not qualify if:
- Prior use of GLP-1 agonist
- Past history of pancreatitis
- Personal or family history of medullary thyroid cancer
- Pregnancy or lactation
- Acute coronary syndrome
- Hepatic or renal dysfunction
- Active malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Madina Women's Hospital
Alexandria, 21531, Egypt
Related Publications (1)
Thakur U, Bhansali A, Gupta R, Rastogi A. Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study. Obes Surg. 2021 Jan;31(1):84-92. doi: 10.1007/s11695-020-04850-4. Epub 2020 Jul 12.
PMID: 32656729BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Ass. Prof. of General surgery
Study Record Dates
First Submitted
March 9, 2022
First Posted
March 17, 2022
Study Start
March 10, 2022
Primary Completion
September 1, 2022
Study Completion
September 1, 2022
Last Updated
March 17, 2022
Record last verified: 2022-03